Carvedilol for Psychostimulant Dependence

This study has been completed.
National Institute on Drug Abuse (NIDA)
Baylor College of Medicine
Information provided by (Responsible Party):
University of Arkansas Identifier:
First received: July 27, 2010
Last updated: July 29, 2015
Last verified: July 2015

July 27, 2010
July 29, 2015
August 2010
May 2014   (final data collection date for primary outcome measure)
Urine Toxicology Screens [ Time Frame: based on thrice weekly urine results during the 10-week outpatient phase ] [ Designated as safety issue: No ]
Treatment Effectiveness Score, defined by the # of cocaine negative urines during the outpatient phase of the study divided by the total number of urine samples (30) and then multiplied by 100.
Urine Toxicology Screens [ Time Frame: thrice weekly for 12 weeks ] [ Designated as safety issue: No ]
cocaine use, as measured by thrice-weekly urine toxicology screens
Complete list of historical versions of study NCT01171183 on Archive Site
Retention [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
number of weeks each participant is on study protocol
  • Retention [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    number of weeks each participant is on study protocol
  • withdrawal symptoms [ Time Frame: thrice weekly during weeks 1 and 2 ] [ Designated as safety issue: No ]
  • orthostatic blood pressure [ Time Frame: thrice weekly for 15 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Carvedilol for Psychostimulant Dependence
Clinical Efficacy of Carvedilol for Psychostimulant Dependence
This study examines whether carvedilol prolongs abstinence in recently abstinent cocaine dependent participants.
Not Provided
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Cocaine Dependence
  • Cocaine Withdrawal
  • Drug: controlled release carvedilol
    carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
    Other Name: Coreg CR
  • Drug: Placebo
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Active Comparator: Carvedilol controlled release
    controlled release carvedilol (Coreg CR) at 80 mg/day in once daily dosing
    Intervention: Drug: controlled release carvedilol
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2014
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18-45 years old
  • Cocaine dependence, as assessed by the substance abuse section of the Structured Clinical Interview for DSM-IV.
  • At least weekly self-reported cocaine use during a preceding three month period
  • Urine toxicology screen positive for cocaine or cocaine metabolite
  • Women of childbearing age must have a negative pregnancy test, agree to adequate contraception to prevent pregnancy during the study, agree to monthly pregnancy testing and not be nursing

Exclusion Criteria:

  • Suicide attempts within the past 12 months or suicidal ideations or psychotic symptoms in the past 6 months as determined by a study physician.
  • Current opioid, alcohol or sedative physical dependence or amphetamine dependence.
  • Major cardiovascular disorder that contraindicates study participation (e.g., history of myocardial infarction, stroke, congestive heart failure, cardiac arrhythmia, significant hypertension [i.e., >170 SBP or >110 DBP] or an unstable medical condition (e.g., untreated bacterial infection) as determined by the study physician.
  • Asthma or chronic obstructive pulmonary disease.
  • History of schizophrenia, or bipolar type I disorder.
  • Use of medications that would be expected to have major interaction with carvedilol (e.g., rifampin, cimetidine, digoxin, diuretics).
  • Medical contraindication to receiving carvedilol (e.g., diabetes, severe bradycardia, bronchial asthma or other bronchospastic condition, 2nd or 3rd degree AV block, sick sinus rhythm, severe hepatic impairment, documented hypersensitivity to carvedilol).
  • Patients currently taking selective serotonin re-uptake inhibitors, antipsychotics and antidepressants (e.g., amitriptyline and imipramine).
  • Liver function tests (i.e., liver enzymes) greater than three times normal levels.
  • Systolic blood pressure > 170 mmHg or < 90 mmHg, diastolic blood pressure > 110 mmHg or < 60 mmHg, or heart rate of > 110 beats/min or < 55 beats/min. Supine blood pressure of 100/65 mm Hg or lower, a seated blood pressure of 90/60 mm Hg or lower, or an orthostatic change of >20mm Hg systolic or 10 mm Hg diastolic on standing.
  • Participants with estimated glomerular filtration rate < 30 ml/min.
  • Pregnant or nursing female.
18 Years to 45 Years
Contact information is only displayed when the study is recruiting subjects
United States
2 P50 DA018197, 2P50DA018197
University of Arkansas
University of Arkansas
  • National Institute on Drug Abuse (NIDA)
  • Baylor College of Medicine
Not Provided
University of Arkansas
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP